European Journal of Clinical Pharmacology

, Volume 20, Issue 6, pp 413–416

Reduction of menopausal hot flushes by methyldopa

A double blind crossover trial
  • B. -I. Nesheim
  • T. Sætre
Originals

DOI: 10.1007/BF00542092

Cite this article as:
Nesheim, B.-. & Sætre, T. Eur J Clin Pharmacol (1981) 20: 413. doi:10.1007/BF00542092

Summary

In a double-blind study, methyldopa was shown to be significantly more effective than placebo in reducing menopausal hot flushes. The median reduction in the number of hot flushes was 38% with placebo and 65% with methyldopa. The active metabolite of methyldopa, alpha-methylnoradrenaline, is an alpha2-adrenoceptor agonist. Since the alpha2-adrenoceptor agonist clonidine also reduces hot flushes, while the alpha2-adrenoceptor antagonist yohimbine produces flushes, it is speculated that menopausal hot flushes might result from a reduced stimulation of alpha2-adrenoceptors, probably in the CNS.

Key words

methyldopamenopausehot flushesalpha2-adrenoceptor agonist

Copyright information

© Springer-Verlag 1981

Authors and Affiliations

  • B. -I. Nesheim
    • 1
  • T. Sætre
    • 1
  1. 1.Department of Gynaecology and Obstetrics, Akershus Central HospitalUniversity of OsloNorway